Mark Moody, Ph.D. of Activate will present “Nanomedicine Formulations for Delivery of TLR Agonist Drug Combinations” at the May 9-11 STING&TLR-Targeting Therapies conference in Boston.
Continue Reading
Brian Horsburgh, Activate’s CEO, presented on the company’s technology and pipeline at the Biotech Showcase in San Francisco.
Continue ReadingMark Moody, Ph.D. of Activate presented “Nanomedicine Formulations for TLR Agonist Drug Combinations” at the March 22-24 STING&TLR-Targeting Therapies conference.
Continue Reading